Disclaimer

The alfapump® system is currently not approved in the United States or Canada. In the United States and Canada, the alfapump® system is currently under clinical investigation (POSEIDON Study) and is being studied in adult patients with refractory or recurrent ascites due to cirrhosis. DSR® therapy is still in development and it should be noted that any statements regarding safety and efficacy arise from ongoing pre-clinical and clinical investigations which have yet to be completed. There is no link between the DSR® therapy and ongoing investigations with the alfapump® system in Europe, the United States or Canada.

In the news

Kanaal Z – 14/09/2023
Interview with Kris Kippers (Degroof Petercam)

Watch video

Edison TV – 15/11/2022
Sequana Medical – executive interview

Watch video

Podcast with Ian Crosbie – 21/01/2022
“Water, Water, Everywhere – Innovations in Treating Diuretic Resistant Fluid Overload” featuring Ian Crosbie

Listen podcast

Bolero Biotech event – October 2021
Bolero Biotech Event featuring Ian Crosbie, CEO Sequana Medical – timeslot 00:43:12 – 01:21:27

Watch video

De Belegger on Tour – 20/09/2021
Pitch Ian Crosbie during “De Belegger on tour”

Go to news

Edison TV – 28/07/2021
Sequana Medical – executive interview

Go to news

Kanaal Z – 04/02/2021
Sequana Medical opent deur naar behandeling hartaandoeningen

Go to news

Kanaal Z – 23/01/2020
Sequana haalt forst kapitaal op, aan forse korting ook

Go to news

Kanaal Z – 15 /10/2018
Zwitsers medtechbedrijf Sequana kiest voor Gent

Go to news

PRESS RELEASES

SUBSCRIBE TO OUR PRESS RELEASES